182181-36-8

Usage

Appearance

White crystalline solid A solid substance with a white, crystal-like appearance.

Molecular weight

217.69 g/mol The mass of one mole of 2-(1-piperazinyl)-5-chlorobenzonitrile, which is approximately 217.69 grams.

Pharmaceutical use

Building block for drug synthesis Widely used in the pharmaceutical industry as an intermediate compound for the synthesis of various drugs.

Medicinal applications

Antipsychotic and antidepressant medications Commonly used in the development of drugs for treating mental health disorders, such as psychosis and depression.

Therapeutic potential

Neurological disorders and cancer Has been studied for its potential to treat various medical conditions, including neurological disorders and cancer.

Stability

High stability The compound is known for its ability to maintain its chemical properties and resist change under various conditions.

Volatility

Low volatility 2-(1-piperazinyl)-5-chlorobenzonitrile does not easily vaporize or become airborne, making it suitable for use in drug formulations and chemical reactions.

Handling precautions

Potential health hazards and environmental impacts It is important to handle this chemical with care, as it may pose risks to human health and the environment.

Upstream product

• 849106-84-9 4-(4-chloro-2-cyano-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 144-55-8 sodium hydrogencarbonate 
• 110-85-0 piperazine 
• 21663-61-6 2,5-dichlorobenzonitrile 
• 57381-34-7 5-chloro-2-fluorobenzonitrile 
• 111373-03-6 2-(piperazin-1-yl)benzonitrile 
• 179250-25-0 4-(2-cyano-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 182180-83-2 5-Chloro-2-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]-1-piperazinyl]benzonitrile 

Relevant academic research and scientific papers

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

NOVEL COMPOUNDS

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating diseases and conditions mediated by positive allosteric modulation of the G- protein coupled metabotropic subtype 5 receptor (mGluR5), such as neur

Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor

Benzylamine and pyridinemethylamine derivatives were synthesized and characterized as potent and selective antagonists of the melanocortin-4 receptor (MC4R). These compounds were also profiled in rodents for their pharmacokinetic properties. Two compounds with diversified profiles in chemical structure, pharmacological activities, and pharmacokinetics, 10 and 12b, showed efficacy in an established murine cachexia model. For example, 12b had a Ki value of 3.4 nM at MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, including high brain penetration. Moreover, 12b was able to stimulate food intake in the tumor-bearing mice and reverse their lean body mass loss. Our results provided further evidence that a potent and selective MC4R antagonist with appropriate pharmacokinetic properties might potentially be useful for the treatment of cancer cachexia.

Chemokine receptor antagonists and methods of use thereof

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES

The present invention relates to imidazo[1,2-a]pyridine compounds of formula (1) STR1 which are dopamine D-4 antagonists and useful as anti-psychotic agents.